COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Cutivate Lotion HPA Axis Pediatric Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00546000
Recruitment Status : Completed
First Posted : October 18, 2007
Results First Posted : July 24, 2014
Last Update Posted : July 24, 2014
Information provided by (Responsible Party):
Fougera Pharmaceuticals Inc.

Brief Summary:
A multi-center, open-label, Phase IV, unblinded study using Cutivate (fluticasone propionate, 0.05%)lotion and it's possible effects on the HPA axis of infants diagnosed with atopic dermatitis.

Condition or disease Intervention/treatment Phase
Atopic Dermatitis Drug: Fluticasone propionate 0.05% lotion Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 56 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-Center, Open-Label Study to Evaluate the Effect of ALTANA Inc's Cutivate (Fluticasone Propionate) Lotion 0.05% on the Hypothalmic Pituitary Adrenal (HPA) Axis in the Treatment of Atopic Dermatitis in a Pediatric Population
Study Start Date : July 2007
Actual Primary Completion Date : December 2008
Actual Study Completion Date : December 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eczema

Arm Intervention/treatment
Experimental: 1
Receive between 22 and 29 days of Cutivate lotion treatment
Drug: Fluticasone propionate 0.05% lotion
Daily applications

Primary Outcome Measures :
  1. Post Treatment Serum Cortisol Values Will be Compared. [ Time Frame: Up to 29 days of treatment ]
    The primary safety parameter was the response to the CST at the end of treatment/final visit. Blood samples were collected prior to injection of cosyntropin and post-injection. Post-CST stimulation cortisol level ≤ 18micrograms/dL was considered as evidence of adrenal suppression.

Secondary Outcome Measures :
  1. Record Skin Atrophy, Pigmentation Change, Hematological and Chemistry Assessments, and Changes in Atopic Dermatitis Severity [ Time Frame: Over 5-6 visits following the baseline visit through the end of treatment between Day 22-29 ]
    The frequency distributions of the presence/absence of adverse events associated with signs of atrophy and pigmentation changes were summarized with frequency counts. Hematology and Chemistry Assessments were summarized in shift tables. Signs and symptoms of AD were summarized at each visit.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   3 Months to 12 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects are 3-12 months of age
  • Subjects diagnosed with Atopic Dermatitis (AD) and have ≥35% of Body Surface Area
  • Subjects meet protocol specific AD signs and symptom severity score

Exclusion Criteria:

  • Subjects with conditions effecting the HPA Axis
  • Subjects with clinically significant systemic disease
  • Subjects who require treatment with systemic or topical retinoids during the study
  • Subjects who have been treated with various chronic therapies identified in the protocol
  • Subjects who have received other investigational drug treatment within 30 days prior to study entry

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00546000

Layout table for location information
United States, California
Centre for Health Care Medical Associates
Poway, California, United States, 92064
Rady Children's Hospital, San Diego
San Diego, California, United States, 92123
United States, Florida
University of Miami, Dept. of Dermatology
Miami, Florida, United States, 33125
United States, Kansas
Adult & Pediatric Dermatology
Overland Park, Kansas, United States, 66211
United States, Minnesota
Dermatology Center for Children and Young Adults
Eagan, Minnesota, United States, 55121-1176
United States, Missouri
Central Dermatology
Saint Louis, Missouri, United States, 63117
United States, North Carolina
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States, 27157
United States, Pennsylvania
Paddington Testing Company, Inc
Philadelphia, Pennsylvania, United States, 19103
United States, Texas
University of Texas Medical Branch
Galveston, Texas, United States, 77555-0783
University of Texas Health Science Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
Fougera Pharmaceuticals Inc.
Layout table for investigator information
Principal Investigator: Alan Fleischer Jr., M.D. Wake Forest University Health Sciences
Principal Investigator: Lawrence F. Eichenfield, MD Rady Children's Hospital, San Diego
Principal Investigator: Elizabeth Connelly, MD University of Miami
Principal Investigator: Craig L. Leonardi, MD Central Dermatology
Principal Investigator: Lawrence Parish, MD Paddington Testing Company, Inc
Principal Investigator: Adelaide A Hebert, MD The University of Texas Health Science Center, Houston
Principal Investigator: Sharon Raimer, MD University of Texas Medical Branch, Galveston
Principal Investigator: Kenneth E. Bloom, MD Dermatology Center for Children and Young Adults
Principal Investigator: David L Kaplan, MD Adult & Pediatric Dermatology
Principal Investigator: Stephen W. Shewmake, M.D. Centre for Health Care Medical Associates
Layout table for additonal information
Responsible Party: Fougera Pharmaceuticals Inc. Identifier: NCT00546000    
Other Study ID Numbers: ALT 0434-01-01
First Posted: October 18, 2007    Key Record Dates
Results First Posted: July 24, 2014
Last Update Posted: July 24, 2014
Last Verified: June 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Dermatitis, Atopic
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Immune System Diseases
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Dermatologic Agents
Anti-Allergic Agents